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Aims: Blood-brain-barrier (BBB) disruption is a crucial process in stroke, but no effective drug 
is available. Thus, drug discovery targeting BBB permeability becomes timely important. In 
this study, we hypothesized that Nitric oxide (NO)/Cav-1/Matrix metalloproteinase (MMP) 
pathway is important therapeutic targets in preventing BBB disruption. Following, we 
investigated the effects of CG, an active compound isolated from Astragali Radix on regulating 
this pathway and protecting BBB permeability and brain damage during cerebral 
ischemia-reperfusion injury.   
Methods: SD rats were subject to different time courses of middle cerebral artery occlusion 
(MCAO). We investigated the expressions of cav-1 and NOS, the production of NO and 
peroxynitrite, activation of MMP-9, tight-junction (TJ) protein, BBB permeability and 
infarction volume in rat and mouse models of cerebral ischemia-reperfusion injury in vivo and 
hypoxic rat brain microvascular endothelial cells (BMECs) in vitro. CG (60 μmol/kg, i.p.) was 
used at 15 min before ischemia.  
Results: (1) NO production reduced cav-1 expression, and the decreased cav-1 was associated 
with further increases of NO and peroxynitrite production, MMP-2/9 activation, TJ protein 
degradation and BBB hyper-permeability. (2) L-NAME, a non-selective NOS inhibitor, 
abolished the cav-1 reduction, MMP-2/9 activations, microvascular hyperpermeability and 
reduced infarction sizes in the ischemic brains. (3) Cav-1 knockdown by siRNA increased the 
secretion of MMP-2 to the culture medium. (4) After focal cerebral ischemia-reperfusion, cav-1 
deficiency mice displayed higher MMPs activities and BBB permeability than wild-type mice. 
(5) The effects of L-NAME on MMPs activity and BBB permeability was partly reversed in 
cav-1 deficiency mice. (6) CG treatment decreased NO and MMPs activation, protected cav-1, 
reduced infarction volume, BBB permeability and brain damage.   
Conclusion: Nitric oxide/Cav-1/MMP pathway is an important signal pathway in BBB 
disruption. The interaction of reactive nitrogen species, cav-1 and MMPs forms a positive 
feedback loop which provides amplified impacts on BBB dysfunction during cerebral 
ischemia-reperfusion injury. CG is a potential drug candidate for protecting BBB and reducing 
infarction volume in ischemic stroke treatment.    
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